Navigation Links
Pharma Pricing and Market Access News from HealthEconomics.Com for December 20, 2013
Date:12/20/2013

Ponte Vedra Beach, FL (PRWEB) December 20, 2013

The December 17, 2013 newsletter from HealthEconomics.Com explored whether the growing need for health outcomes studies will lead to increased research and development costs, and potentially strain the already heavily scrutinized drug development budgets. Health Outcomes studies may last 3-6 years and cost as much as $500 million and include between 10,000 and 25,000 patients, according to Forbes.Com’s article by John LaMattina on December 2, 2013. Despite these costs, pharmaceutical outcome studies are in growing demand not just by regulators and payers, but also patients and clinicians, because they provide data on the real value of the medicines as well as more real-world effectiveness data that is not currently addressed by tightly controlled clinical trials.

Another article in the HealthEconomics.Com Newsletter took a look at what healthcare might look like in 2014, based on a recently released publication by the Healthcare Intelligence Network entitled “Healthcare Trends & Forecasts in 2014: Performance Expectations for the Healthcare Industry”. The publication includes a planning tool for executives called the “pyramid of success” utilized to help assess the industry landscape for physicians and hospitals, including the impact of accountable care organizations, medical homes, and other trends. The future for health plans are examined, including the changes in primary care and sector-by-sector impact from the health insurance changes.

Lastly, a White Paper entitled “Counter Brand Revenue Erosion from Generics through Defensive Pricing Strategies” by Cutting Edge Information is examined, in which defensive pharmaceutical pricing strategies are reviewed for use to counter threats from low-priced generic alternatives. The white paper also covers pricing strategies that can be utilized to effectively support future generic competition.

About HealthEconomics.Com (http://www.healtheconomics.com):
A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for life sciences professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.

News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com by visiting the site or by clicking on the following link: Subscribe to HealthEconomics.Com Newsletter.

Read the full story at http://www.prweb.com/releases/HealthEconomicsCom/topstories/prweb11440323.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. HealthEconomics.Com Launches Live Streaming Educational Series in HE-Xpo®, the Pharma Industry’s Only Online Virtual Community for Health Economics and Outcomes Research
2. Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
3. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
4. Americas Pharmaceutical Market Forecasts to 2018
5. Industry Shares, Size, Trend, Analysis, and Forecasts to 2018 Report Available Online by Researchmoz.us
6. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
7. The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
8. Hart-Scott-Rodino Waiting Period Expires for Shires Acquisition of ViroPharma
9. WavePharma Unveils Proprietary Chitosan-Based Delivery System for Controlled Release of Key Ingredients in Personal Care Products
10. PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022
11. JCB Laboratories Debuts High Tech Monitoring System That Will Further Enhance Patient Safety, Surpass Compounding Pharmacy Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016  Spherix Incorporated (Nasdaq: SPEX ) -- an ... monetization of intellectual property, today provided an update on ... Northern District of Texas and ... Inter Partes Re-examination ("IPR") proceedings that VTech ... IPR was initiated on only certain claims of two ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
(Date:2/3/2016)... Pa. , Feb. 3, 2016  Discovery ... company focused on developing aerosolized KL4 surfactant therapies ... of Directors has approved an inducement award as ... Fraser , its newly appointed President and Chief ... Board,s Compensation Committee on February 1, 2016 and ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 Harvard ... a biotechnology company developing bioengineered organ implants for ... today announced that CEO Jim McGorry , ... Investor Conference on Tuesday, February 9, 2016 ... York City . HART,s presentation will be ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
(Date:2/1/2016)... , February 1, 2016 Rising ... to drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new ... market size through 2020   ... coupled with new technological advancements to drive global touchfree ...
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
Breaking Biology News(10 mins):